Journal of Clinical Oncology · 1988 · 122 citations · 9 references
PharmacyPharmacologyPharmacotherapyCancer PharmacologyChemotherapyOncology PharmacotherapyAdverse Effects Of ChemotherapyAntiemetic TherapyChemotherapy Dosing SafetyChemotherapy Drug AdministrationChemotherapy Toxicity ManagementCytotoxic ChemotherapyAnticancer ActivityAnticancer ChemotherapyAntiemetic ResponseChemotherapy-related ToxicityDosage LevelsIntravenous Chemotherapy DosingMedication-related Dry MouthSerum Alanine Aminotransferase
GR-C507/75 (GR38032F) antagonizes the 5-HT3 (serotonin) receptor and prevents cisplatin-induced emesis in animals. In this dose-ranging trial, 44 patients with cancer receiving chemotherapy known to produce nausea and vomiting (including cisplatin, cyclophosphamide, and doxorubicin) received three intravenous (IV) infusions of GR-C507/75 every two hours beginning 30 minutes before chemotherapy. Ten dosage levels were explored, ranging from 0.04 mg/kg to 0.35 mg/kg in each of the three infusions. Toxicities were mild and included sedation, dizziness, headache, transient elevations of SGOT or alanine aminotransferase (ALT), and dry mouth. No akathisia or acute dystonic reactions were observed. Antiemetic effects were seen in patients receiving cisplatin at 120 mg/m2. GR-C507/75 can be safely administered on this schedule at IV dosages up to 0.35 mg/kg in patients receiving chemotherapy. Further studies of this agent at higher dosages and by different schedules are appropriate.
9
Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine
Philip Bradley, G. Engel, W. Feniuk et al. · Neuropharmacology · 1986 · 1.3K citations
Medicine, Neuroscience, Pharmacology +12
Richard J. Gralla, Loretta M. Itri, Sharon E. Pisko et al. · New England Journal of Medicine · 1981 · 710 citations
Antiemetic Efficacy of Dexamethasone
Maurie Markman, Vivian R. Sheidler, David S. Ettinger et al. · New England Journal of Medicine · 1984 · 178 citations